Nifty
:
26013.45
Sensex
:
84950.95
103.40 (0.40%)
388.17 (0.46%)
Nifty
Sensex
:
:
26013.45
84950.95
103.40 (0.40%)
388.17 (0.46%)

Granules India Ltd.

Pharmaceuticals & Drugs - API

Rating :
64/99

BSE: 532482 | NSE: GRANULES

NSE BSE
561.70
17-Nov-2025
  • Open
  • High
  • Low
  • Previous Close
  •  550.3
  •  563.8
  •  545.3
  •  548.20
  • Volume
  • Traded Value (lacs)
  • 52 Week High
  • 52 Week Low
  •  612104
  •  338818487.95
  •  628
  •  422

Stock Summary

  • Market Cap(Crs)
  • Stock P:E
  • Face Value
  • 13,624.64
  • 26.57
  • 1
  • Enterprise Value(Crs)
  • Dividend Yield
  • Price:Book Value
  • 14,643.06
  • 0.27%
  • 3.42

Shareholding Pattern

  • Promoter
  • Corporate
  • Public
  • 38.82%
  • 6.62%
  • 18.28%
  • FII
  • DII
  • Others
  • 14.09%
  • 17.13%
  • 5.06%

Chart

Price | P:E | P:BV | EV:EBITDA | MCap:Sales | EPS

Revenue CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • 12.69
  • 6.72
  • -0.22

EBITDA CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • 13.10
  • 2.02
  • 0.69

PAT CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • 14.91
  • -1.81
  • -0.98

P:E (Median)

  • 8 Years
  • 5 Years
  • 3 Years
  • 17.23
  • 18.47
  • 24.72

P:BV (Average)

  • 8 Years
  • 5 Years
  • 3 Years
  • 3.00
  • 3.41
  • 3.32

EV:EBITDA (Average)

  • 8 Years
  • 5 Years
  • 3 Years
  • 11.30
  • 11.88
  • 12.58

Earnings Forecasts:

(Updated: 08-11-2025)
Description
2024
2025
2026
2027
Adj EPS
20.69
22.43
28.35
35.33
P/E Ratio
27.15
25.04
19.81
15.90
Revenue
4481.61
5091.67
5799.57
6651.35
EBITDA
945.24
1069.2
1293.57
1534.33
Net Income
501.52
544.08
687.38
856.53
ROA
8.52
P/B Ratio
3.67
3.22
2.80
2.38
ROE
14.45
13.2
14.53
15.55
FCFF
195
-166.84
208.71
290.57
FCFF Yield
1.33
-1.13
1.42
1.98
Net Debt
842.63
1075.75
1041.05
827.35
BVPS
153.19
174.21
200.9
236.17

Quarterly Results

Consolidated Figures in Rs. Crores /

Standalone
Description
Sep 25
Sep 24
Var%
Jun 25
Jun 24
Var%
Mar 25
Mar 24
Var%
Dec 24
Dec 23
Var%
Net Sales
1,296.99
966.62
34.18%
1,210.11
1,179.87
2.56%
1,197.43
1,175.78
1.84%
1,137.70
1,155.58
-1.55%
Expenses
1,018.76
763.30
33.47%
963.39
920.60
4.65%
945.07
920.08
2.72%
907.40
905.10
0.25%
EBITDA
278.23
203.32
36.84%
246.72
259.27
-4.84%
252.36
255.70
-1.31%
230.29
250.48
-8.06%
EBIDTM
21.45%
21.03%
20.39%
21.97%
21.07%
21.75%
20.24%
21.68%
Other Income
-1.15
3.25
-
16.34
2.06
693.20%
1.92
1.87
2.67%
5.68
0.65
773.85%
Interest
29.19
25.67
13.71%
23.78
27.02
-11.99%
23.98
28.76
-16.62%
26.57
28.65
-7.26%
Depreciation
72.02
52.52
37.13%
68.85
52.87
30.23%
63.50
53.18
19.41%
56.61
52.39
8.05%
PBT
175.87
128.38
36.99%
144.53
181.44
-20.34%
197.55
175.64
12.47%
152.79
170.09
-10.17%
Tax
45.26
31.15
45.30%
31.89
46.79
-31.84%
45.52
45.99
-1.02%
35.19
44.44
-20.81%
PAT
130.61
97.23
34.33%
112.64
134.65
-16.35%
152.03
129.65
17.26%
117.60
125.65
-6.41%
PATM
10.07%
10.06%
9.31%
11.41%
12.70%
11.03%
10.34%
10.87%
EPS
5.38
4.01
34.16%
4.64
5.56
-16.55%
6.27
5.35
17.20%
4.85
5.18
-6.37%

Annual Results

Consolidated Figures in Rs. Crores /

Standalone
Description
TTM
Mar 25
Mar 24
Mar 23
Mar 22
Mar 21
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Net Sales
4,842.23
4,481.61
4,506.37
4,511.92
3,764.92
3,237.54
2,598.65
2,279.20
1,684.62
1,410.57
1,357.18
Net Sales Growth
8.14%
-0.55%
-0.12%
19.84%
16.29%
24.59%
14.02%
35.29%
19.43%
3.93%
 
Cost Of Goods Sold
1,744.09
1,725.70
2,021.25
2,307.28
1,883.64
1,391.28
1,280.93
1,255.56
896.32
679.63
725.03
Gross Profit
3,098.14
2,755.91
2,485.12
2,204.63
1,881.28
1,846.27
1,317.72
1,023.64
788.30
730.93
632.15
GP Margin
63.98%
61.49%
55.15%
48.86%
49.97%
57.03%
50.71%
44.91%
46.79%
51.82%
46.58%
Total Expenditure
3,834.62
3,536.37
3,650.39
3,598.60
3,043.30
2,382.31
2,073.33
1,895.16
1,406.20
1,111.73
1,081.29
Power & Fuel Cost
-
100.74
100.64
95.69
74.66
68.85
59.74
57.67
48.22
38.67
34.97
% Of Sales
-
2.25%
2.23%
2.12%
1.98%
2.13%
2.30%
2.53%
2.86%
2.74%
2.58%
Employee Cost
-
619.66
550.24
420.35
366.44
324.29
259.04
209.82
165.21
140.19
117.57
% Of Sales
-
13.83%
12.21%
9.32%
9.73%
10.02%
9.97%
9.21%
9.81%
9.94%
8.66%
Manufacturing Exp.
-
469.82
408.01
273.93
298.74
228.39
177.94
157.62
120.84
88.60
66.97
% Of Sales
-
10.48%
9.05%
6.07%
7.93%
7.05%
6.85%
6.92%
7.17%
6.28%
4.93%
General & Admin Exp.
-
279.35
211.99
187.96
134.41
172.28
125.63
99.96
83.05
67.65
60.38
% Of Sales
-
6.23%
4.70%
4.17%
3.57%
5.32%
4.83%
4.39%
4.93%
4.80%
4.45%
Selling & Distn. Exp.
-
297.79
290.63
280.00
247.45
159.80
112.17
91.84
83.08
81.37
67.75
% Of Sales
-
6.64%
6.45%
6.21%
6.57%
4.94%
4.32%
4.03%
4.93%
5.77%
4.99%
Miscellaneous Exp.
-
43.32
67.62
33.38
37.96
37.42
57.88
22.69
9.49
15.61
67.75
% Of Sales
-
0.97%
1.50%
0.74%
1.01%
1.16%
2.23%
1.00%
0.56%
1.11%
0.64%
EBITDA
1,007.60
945.24
855.98
913.32
721.62
855.23
525.32
384.04
278.42
298.84
275.89
EBITDA Margin
20.81%
21.09%
18.99%
20.24%
19.17%
26.42%
20.22%
16.85%
16.53%
21.19%
20.33%
Other Income
22.79
12.92
4.40
14.29
18.22
26.88
36.56
26.68
10.84
9.93
5.62
Interest
103.52
103.24
105.82
55.93
23.21
26.28
27.02
28.46
33.06
32.26
37.07
Depreciation
260.98
225.50
207.33
184.49
158.63
151.46
136.95
105.48
76.20
71.51
58.40
PBT
670.74
629.42
547.23
687.17
558.00
704.36
397.90
276.78
180.00
204.99
186.03
Tax
157.86
158.65
141.92
170.58
145.24
154.91
115.73
89.11
63.40
65.20
61.15
Tax Rate
23.54%
24.03%
25.93%
24.82%
26.03%
21.99%
27.19%
32.20%
35.22%
31.81%
32.87%
PAT
512.88
501.52
405.31
516.60
412.76
549.46
309.91
187.67
116.60
139.79
124.89
PAT before Minority Interest
512.88
501.52
405.31
516.60
412.76
549.46
309.91
187.67
116.60
139.79
124.89
Minority Interest
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
PAT Margin
10.59%
11.19%
8.99%
11.45%
10.96%
16.97%
11.93%
8.23%
6.92%
9.91%
9.20%
PAT Growth
5.28%
23.74%
-21.54%
25.16%
-24.88%
77.30%
65.14%
60.95%
-16.59%
11.93%
 
EPS
21.13
20.66
16.70
21.29
17.01
22.64
12.77
7.73
4.80
5.76
5.15

Results Balance Sheet

Consolidated Figures in Rs. Crores /

Standalone
Description
Mar 25
Mar 24
Mar 23
Mar 22
Mar 21
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Shareholder's Funds
3,715.58
3,225.54
2,834.91
2,586.54
2,173.27
1,843.72
1,529.47
1,304.18
903.60
661.60
Share Capital
24.25
24.24
24.20
24.80
24.77
25.42
25.42
25.38
22.87
21.67
Total Reserves
3,677.62
3,183.00
2,792.68
2,545.01
2,126.23
1,800.02
1,493.09
1,273.38
878.28
611.13
Non-Current Liabilities
465.99
176.04
254.73
282.83
366.30
485.98
552.63
488.19
187.99
246.62
Secured Loans
311.51
68.97
148.64
233.70
333.81
414.83
478.78
433.13
123.90
183.66
Unsecured Loans
0.00
0.00
0.00
0.00
0.00
6.69
0.00
0.00
0.34
0.55
Long Term Provisions
31.76
37.88
29.26
28.31
24.84
21.50
12.58
7.70
7.25
5.58
Current Liabilities
2,003.16
2,082.29
1,813.50
1,641.60
1,173.10
893.40
896.48
877.91
787.13
654.75
Trade Payables
726.07
749.53
782.13
638.61
541.05
356.88
323.48
274.35
215.98
181.10
Other Current Liabilities
304.61
261.08
193.19
200.85
194.25
153.16
113.60
69.84
93.43
79.21
Short Term Borrowings
922.56
1,054.24
810.88
765.58
409.27
371.69
454.21
525.10
473.83
392.85
Short Term Provisions
49.92
17.45
27.31
36.56
28.53
11.66
5.20
8.62
3.90
1.58
Total Liabilities
6,184.73
5,483.87
4,903.14
4,511.53
3,712.67
3,223.10
2,978.58
2,670.28
1,878.72
1,562.97
Net Block
2,426.47
2,095.62
1,910.92
1,541.17
1,332.00
1,203.97
944.25
776.73
644.34
559.94
Gross Block
3,882.08
3,351.81
2,981.22
2,461.77
2,145.15
1,875.23
1,472.94
1,199.63
983.66
822.98
Accumulated Depreciation
1,455.61
1,256.19
1,070.30
920.59
813.15
671.26
528.69
422.90
339.32
263.05
Non Current Assets
3,069.25
2,578.83
2,328.99
2,006.54
1,715.68
1,594.41
1,696.34
1,483.71
1,050.55
744.97
Capital Work in Progress
440.19
271.70
239.39
356.23
239.08
294.20
495.95
514.52
267.43
76.56
Non Current Investment
22.04
21.52
21.21
19.67
18.99
19.34
210.42
156.56
108.23
70.11
Long Term Loans & Adv.
179.51
190.00
157.47
89.47
125.61
76.89
45.72
35.91
30.56
38.37
Other Non Current Assets
1.04
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Current Assets
3,115.48
2,905.05
2,574.15
2,504.99
1,997.00
1,628.70
1,282.24
1,186.57
828.16
818.00
Current Investments
0.00
0.00
0.00
0.00
0.00
109.85
0.00
0.00
0.00
0.00
Inventories
1,342.82
1,300.55
1,149.41
978.55
782.18
438.43
384.21
279.95
269.18
253.72
Sundry Debtors
942.22
985.83
948.54
924.95
765.42
662.04
673.54
628.25
417.70
375.35
Cash & Bank
596.38
386.38
312.79
409.46
271.04
283.94
89.04
115.64
49.80
130.29
Other Current Assets
234.06
46.28
49.22
61.67
178.35
134.43
135.45
162.73
91.49
58.65
Short Term Loans & Adv.
180.15
186.00
114.19
130.35
127.61
91.83
98.46
114.09
51.66
48.68
Net Current Assets
1,112.32
822.75
760.65
863.38
823.90
735.30
385.76
308.65
41.03
163.25
Total Assets
6,184.73
5,483.88
4,903.14
4,511.53
3,712.68
3,223.11
2,978.58
2,670.28
1,878.71
1,562.97

Cash Flow

Consolidated Figures in Rs. Crores /

Standalone
Description
Mar 25
Mar 24
Mar 23
Mar 22
Mar 21
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Cash From Operating Activity
866.57
439.41
738.75
332.06
432.48
476.19
262.24
-0.65
188.24
151.43
PBT
660.17
547.23
687.17
558.00
704.36
425.64
276.78
180.00
204.99
186.03
Adjustment
344.13
328.80
237.69
176.29
194.43
156.88
149.85
107.45
95.14
92.63
Changes in Working Capital
6.02
-246.32
-10.31
-257.19
-274.95
12.75
-75.94
-230.03
-52.37
-79.70
Cash after chg. in Working capital
1,010.32
629.71
914.55
477.11
623.84
595.27
350.69
57.42
247.77
198.97
Interest Paid
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Tax Paid
-143.75
-190.30
-175.80
-145.05
-191.37
-119.08
-88.45
-58.07
-59.53
-47.54
Other Direct Exp. Paid
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Extra & Other Items
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Cash From Investing Activity
-691.29
-360.16
-191.36
-380.12
-277.13
-160.63
-269.82
-462.31
-326.09
-161.65
Net Fixed Assets
-254.98
-101.04
-104.53
-302.61
-204.42
-124.57
-176.36
-282.01
-249.86
-75.62
Net Investments
-340.13
-264.87
-80.00
-5.00
-36.29
-48.78
-431.34
-0.01
13.84
-16.48
Others
-96.18
5.75
-6.83
-72.51
-36.42
12.72
337.88
-180.29
-90.07
-69.55
Cash from Financing Activity
-92.51
7.66
-440.29
190.00
-299.31
-212.85
-17.43
528.62
55.87
85.67
Net Cash Inflow / Outflow
82.77
86.92
107.10
141.94
-143.97
102.70
-25.01
65.66
-81.98
75.44
Opening Cash & Equivalents
381.10
291.56
184.71
41.84
185.93
83.02
108.03
42.37
124.35
54.85
Closing Cash & Equivalent
466.11
381.10
291.56
184.71
41.84
185.93
83.02
108.03
42.37
130.29

Financial Ratios

Consolidated /

Standalone
Description
Mar 25
Mar 24
Mar 23
Mar 22
Mar 21
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Book Value (Rs.)
152.63
132.33
116.38
103.62
86.85
71.80
59.73
51.17
39.40
29.20
ROA
8.60%
7.80%
10.97%
10.04%
15.84%
9.99%
6.64%
5.13%
8.12%
9.03%
ROE
14.52%
13.46%
19.18%
17.49%
27.64%
18.54%
13.32%
10.60%
18.23%
23.53%
ROCE
16.16%
15.66%
19.63%
17.37%
25.42%
17.22%
12.71%
11.09%
16.57%
20.16%
Fixed Asset Turnover
2.06
2.07
1.66
1.63
1.97
1.75
1.78
1.55
1.59
1.66
Receivable days
47.23
53.89
75.78
81.94
65.94
83.34
100.03
112.83
100.84
67.60
Inventory Days
64.75
68.26
86.07
85.35
56.39
51.34
51.03
59.23
66.49
63.11
Payable days
156.05
138.29
112.38
114.29
117.79
58.20
54.96
62.37
64.87
59.99
Cash Conversion Cycle
-44.08
-16.14
49.48
52.99
4.54
76.48
96.10
109.70
102.46
70.72
Total Debt/Equity
0.35
0.38
0.38
0.43
0.39
0.49
0.65
0.75
0.73
1.01
Interest Cover
7.39
6.17
13.29
25.04
27.80
16.75
10.72
6.44
7.36
6.02

Annual Reports:

FY 2025
FY 2024
FY 2023
FY 2022
FY 2021
FY 2020
FY 2019
FY 2018
FY 2017
FY 2016

News Update:


  • Granules India - Quarterly Results
    14th Nov 2025, 00:00 AM

    Read More
  • Granules India’s arm gets first USFDA approval for Hyderabad facility
    11th Nov 2025, 11:53 AM

    The company plans to launch the approved product in the U.S. market soon

    Read More
  • Granules India’s arm gets EIR from USFDA for pre-approval inspection
    5th Nov 2025, 11:45 AM

    There was one observation during the inspection, and it has been resolved

    Read More
  • Granules India gets EIR from USFDA for API unit-I facility in Hyderabad
    29th Oct 2025, 15:41 PM

    The EIR was issued with an inspection classification of Voluntary Action Indicated post the inspection conducted in June 2025

    Read More
  • Granules India’s arm recalls products in US market
    29th Sep 2025, 12:59 PM

    The US-based arm of the company issued the Class III recall on August 28, 2025

    Read More

Source: www.accordfintech.com | DISCLAIMER: Information is provided " as is" and solely for informational purposes, not for trading purposes or advice, and may be delayed.